hA20
Term · Oncology and biomedicine · MLC-T-ONC-003708
A substance being studied in the treatment of several types of lymphoma. It binds to the protein CD20, which is found on B cells (a type of immune system cell) and some types of lymphoma cells. This causes the immune system to kill the cancer cells. hA20 is a type of monoclonal antibody. Also called HCD20, IMMU-106, and veltuzumab.
| Identifier | MLC-T-ONC-003708 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | HCD20; IMMU-106; veltuzumab |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-003708",
"term": "hA20",
"field": "Oncology and biomedicine",
"definition": "A substance being studied in the treatment of several types of lymphoma. It binds to the protein CD20, which is found on B cells (a type of immune system cell) and some types of lymphoma cells. This causes the immune system to kill the cancer cells. hA20 is a type of monoclonal antibody. Also called HCD20, IMMU-106, and veltuzumab.",
"synonyms": [
"HCD20",
"IMMU-106",
"veltuzumab"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/ha20/"
}
Record 8,252 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.